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Abstract
Background: Previously, we have demonstrated that spleen-derived dendritic cells (DCs) modified with atorvastatin
suppressed immune responses of experimental autoimmune myasthenia gravis (EAMG). However, the effects of
exosomes derived from atorvastatin-modified bone marrow DCs (BMDCs) (statin-Dex) on EAMG are still unknown.
Methods: Immunophenotypical characterization of exosomes from atorvastatin- and dimethylsulfoxide (DMSO)-
modified BMDCs was performed by electron microscopy, flow cytometry, and western blotting. In order to investigate
whether statin-DCs-derived exosomes (Dex) could induce immune tolerance in EAMG, we administrated statin-Dex,
control-Dex, or phosphate-buffered saline (PBS) into EAMG rats via tail vein injection. The tracking of injected Dex and
the effect of statin-Dex injection on endogenous DCs were performed by immunofluorescence and flow cytometry,
respectively. The number of Foxp3+ cells in thymuses was examined using immunocytochemistry. Treg cells, cytokine
secretion, lymphocyte proliferation, cell viability and apoptosis, and the levels of autoantibody were also carried out to
evaluate the effect of statin-Dex on EAMG rats. To further investigate the involvement of FasL/Fas in statin-Dex-induced
apoptosis, the underlying mechanisms were studied by FasL neutralization assays.
Results: Our data showed that the systemic injection of statin-Dex suppressed the clinical symptoms of EAMG rats.
These statin-Dex had immune regulation functions in immune organs, such as the spleen, thymus, and popliteal and
inguinal lymph nodes. Furthermore, statin-Dex exerted their immunomodulatory effects in vivo by decreasing the
expression of CD80, CD86, and MHC class II on endogenous DCs. Importantly, the therapeutic effects of statin-Dex on
EAMG rats were associated with up-regulated levels of indoleamine 2,3-dioxygenase (IDO)/Treg and partly dependent
on FasL/Fas pathway, which finally resulted in decreased synthesis of anti-R97–116 IgG, IgG2a, and IgG2b antibodies.
Conclusions: Our data suggest that atorvastatin-induced immature BMDCs are able to secrete tolerogenic Dex, which
are involved in the suppression of immune responses in EAMG rats. Importantly, our study provides a novel cell-free
approach for the treatment of autoimmune diseases.
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Background
Myasthenia gravis (MG) is an autoimmune disorder
characterized by loss of acetylcholine receptor (AChR)
on the postsynaptic membrane of neuromuscular
junction, which results in defect in neuromuscular
transmission and causes muscle weakness and fatigue
[1]. The generation of autoantibodies to AChR is T
cell dependent, in which CD4+ T cells help B cells to
produce anti-AChR autoantibodies [2]. Experimental
autoimmune myasthenia gravis (EAMG) can be
induced in Lewis rats by immunization with Torpedo
acetylcholine receptor (TAChR) or with a synthetic
peptide corresponding to regions 97–116 of the rat
AChR α subunit (R97–116 peptide). This EAMG
model can mimic the human MG [3]. Currently used
therapeutic drugs for MG include corticosteroids, im-
munosuppressants, antisense treatment (Monarsen, a
synthetic antisense compound directed against the
AChE gene) [4], and TNF-α receptor blocker (such as
Etanercept) [5]. The mortality and morbidity of MG
has decreased up to now [6]. Although the
above mentioned drugs are effective in treating MG,
their side effects are very severe. Thus, more effective
drugs are still in urgent need.
Dendritic cells (DCs) are the professional antigen-
presenting cells (APCs) in the immune system. Vaccine
against DCs, a cellular treatment to induce immune tol-
erance, has been studied in different animal models.
AChR-pulsed bone marrow DCs (BMDCs) could induce
peripheral tolerance to EAMG through inhibiting the
expression of B cell activating factor (BAFF) and the
production of anti-AChR autoantibodies [7]. DCs modi-
fied with different cytokines in vitro or with RelB (an
NF-κB family member that is responsible for DCs differ-
entiation) specific small interfering RNA sequences have
shown protective effects on the inhibition of the onset
and progression of autoimmune diseases [8–11]. Statins,
including atorvastatin, are 3-hydroxy-3-methyl-glutaryl
coenzyme A (HMG-CoA) reductase inhibitors in the
mevalonate pathway for cholesterol biosynthesis. In-
creasing evidences have shown that statins have immu-
nomodulatory effects. The effects of statins on immune
system include inhibiting the expression and secretion of
pro-inflammatory cytokines [12], inhibiting T cell activa-
tion and proliferation [13], inhibiting the maturation and
function of APCs [14]. Our previous study demonstrated
that tolerogenic immature DCs could be induced by
atorvastatin in vitro and these tolerogenic DCs success-
fully induced the immune tolerance in EAMG rats [15].
Thus, DCs vaccine may be an effective method for the
treatment of autoimmune diseases. However, there are
some limitations in DCs vaccine treatment. Among
these limitations, the unstable characteristics of DCs
vaccine in vitro is of most importance.
Exosomes are small particles (about 30–100 nm in
size) secreted by different type of cells, such as DCs [16],
T lymphocytes [17], and tumor cells [18]. In recent
years, DCs-derived exosomes (Dex) have gained much
attention in autoimmune diseases and tumors because
they resemble the biology of cells from which they were
derived [19]. There are many important regulatory mole-
cules on Dex, such as MHC class I/II molecules, CD80,
CD86, and CD40 (for antigen presentation and T cell
stimulation) [20, 21]. Depending on the stage of matur-
ation of DCs, there are at least two phenotypes of Dex,
which are mature Dex and immature Dex. Mature Dex
shows immunostimulatory effects [22] while immature
Dex shows immunosuppressive effects [23]. It has been
shown that exosomes derived from tumor peptide-
pulsed DCs cause suppression of tumor growth in mice
[24]. In a phase I study, Dex therapy results in immune
activation and stability in advanced non-small cell lung
cancer [25]. On the other hand, exosomes derived from
immature BMDCs (iDex) ameliorated the progression of
EAMG by reducing AChR-reactive lymphocyte prolifera-
tion, AChR antibody levels and pro-inflammatory cyto-
kine levels [26]. IDex, which carries a moderate level of
MHC class II and a low level of co-stimulatory mole-
cules on their surface, prolong the intestinal allograft
survival, suggesting that they may play important roles
in immune regulation [27]. Indoleamine 2,3-dioxygenase
(IDO) is an intracellular tryptophan-catabolizing rate-
limiting enzyme that has immunosuppressive properties
[28]. IDO can inhibit immune responses by enhancing
apoptosis of T cells, inhibiting proliferation of T cells,
and inducing the differentiation of naïve T cells into
Treg cells [29–32]. It suggests that Dex over-carrying
IDO could improve collagen-induced arthritis (CIA) and
reduce inflammation in the delayed-type hypersensitivity
(DTH) models [33]. Our previous study demonstrated
that spleen-derived DCs modified with atorvastatin
successfully induced the immune tolerance in EAMG
rats. However, the effects of atorvastatin-modified DCs-
derived exosomes (statin-Dex) on immune tolerance are
still unknown.
In this study, we evaluated the effects of statin-Dex on
EAMG and tried to investigate the mechanisms. We
found that systemic administration of statin-Dex was
able to suppress the clinical symptoms of EAMG rats.
All the data suggest that atorvastatin-modified BMDCs
can secrete tolerogenic Dex, and this may provide us a
novel therapeutic approach for autoimmune diseases.
Methods
Animals and reagents
Six- to eight-week-old female Lewis rats (body weight
145–165 g) were purchased from Vital River Laborator-
ies (Beijing, China) and kept under pathogen-free
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conditions at the local animal house. All rats were
housed on a 12/12 light-dark schedule with water and
food available ad libitum. All the experimental protocols
were approved by the guidelines of the Animal Ethics
Committee of Shandong University. Atorvastatin was
kindly given by Beijing Garlin Pharmaceutical Co., Ltd
(Beijing, China). R97–116 peptide (DGDFAIVKFTKVLL-
DYTGHI) was synthesized by AC Scientific, Inc. (Xian,
China).
Generation and culture of BMDCs
The tibia and femur bones were harvested from the on-
going EAMG rats (n = 40) on day 22 post immunization
(p.i.) after removing the muscle tissue. Both ends of the
bones were cut with a scissor, and the bone marrow was
flushed into a new dish with phosphate-buffered saline
(PBS) and passed through a cell strainer (70 μm; Becton
Dickinson, Franklin Lakes, NJ, USA). Then, erythrocytes
were osmotically lysed. Bone marrow cells were further
enriched by differential adherence by incubating cells in
75 mm2 Falcon culture flasks (Becton Dickinson) in
serum-free Roswell Park Memorial Institute (RPMI)
1640 (containing 2.05 mM glutamine, HyClone, Beijing,
China) at 37 °C in a 5 % CO2 incubator. After 1 h
40 min, non-adherent cells were gently removed by swir-
ling the flasks and aspirating the medium, then flasks
were washed with serum-free medium to remove non-
adherent cells. For Dex production, fetal calf serum
(FCS; Gibco, Grand Land, NY, USA) depleted of con-
taminating vesicles and protein aggregates underwent
overnight centrifugation at 110,000×g. Bone marrow
cells were re-suspended in fresh complete medium con-
taining 10 ng/ml recombinant rat granulocyte-
macrophage colony-stimulating factor (rrGM-CSF) and
10 ng/ml recombinant rat IL-4 (rrIL-4) (Peprotech,
Rocky Hill, NJ, USA). Same concentration of fresh
medium was added on day 6. After 10 days of culture,
the floating cells were collected as a DCs-enriched frac-
tion. The DCs-enriched fraction showed approximately
80–85 % DCs by staining with anti-rat OX62 antibody
(Becton Dickinson), which was considered as BMDCs.
Then BMDCs were harvested for atorvastatin treatment.
For atorvastatin treatment, BMDCs were plated on
six-well plates in complete culture medium without
rrGM-CSF and rrIL-4. Atorvastatin dissolved in
dimethylsulfoxide (DMSO, Sigma-Aldrich, St. Louis,
MO, USA) was added to some wells (final concentra-
tion 10 μM, statin-BMDCs). The same volume of
DMSO was added to the other wells (control-
BMDCs). After incubation for 72 h in 37 °C, the
supernatants were harvested for Dex purification. We
found that approximately 3.5–8 μg of exosomes were
obtained from the supernatants of 106 BMDCs for
72 h culture.
Dex purification
Dex were prepared from the cell culture supernatants of
statin-BMDCs (statin-Dex) and control-BMDCs (con-
trol-Dex) by differential centrifugation as described by
Raposo et al. [34]. Briefly, the culture supernatants were
subjected to three successive centrifugations at 300×g
(5 min), 1200×g (20 min), and 10,000×g (30 min) to
eliminate cells and debris in the pellets, followed by cen-
trifugation for 1 h at 100,000×g. To remove excess
serum proteins, the Dex pellets were washed with a large
volume of PBS, centrifuged at 100,000×g for 1 h, and re-
suspended in PBS for further studies. Then, Dex were
quantified by the K5600 MicroSpectroPhotoMeter
(Beijing Kaiao Technology Development Co. Ltd,
Beijing, China), and 1 μg was suspended in 20 μl of PBS
for in vivo studies.
Electron microscopy
Dex were purified by differential centrifugation, 10 μl
loaded on a Formvar/carbon coated grid, negatively
stained with 10 μl of neutral 1 % aqueous phosphotung-
stic acid, and viewed using JEOL-1210 computer-
controlled, high-contrast, 120-kV transmission electron
microscope.
Flow cytometric analysis of Dex
For fluorescence-activated cell sorting (FACS) analysis,
30 μg of statin-Dex or control-Dex (or 30 μg FCS pro-
tein for negative control) were incubated with 10 μl of
4 μm-diameter aldehyde/sulfate latex beads (Invitrogen,
Eugene, OR, USA) for 15 min at room temperature,
followed by 2 h of gentle shaking in PBS. The reaction
was stopped by incubation for 30 min in 100 mM
glycine. Dex- or FCS-coated beads were washed three
times in FACS wash buffer (3 % FCS and 0.1 % NaN3 in
PBS) and re-suspended in 500 μl FACS wash buffer.
Then, 10 μl of coated beads were incubated with phyco-
erythrin (PE)-conjugated anti-rat CD80 (BioLegend, San
Diego, CA, USA), fluorescein isothiocyanate (FITC)-
conjugated anti-rat CD86 (BioLegend), FITC-conjugated
anti-rat MHC class II (eBioscience, San Diego, CA,
USA), and FITC-conjugated anti-rat FasL antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
followed by washing and analysis using an FACScan
(Beckman Coulter, Los Angeles, CA, USA).
Western blotting
Statin-Dex and control-Dex samples (10 μg/lane) were
loaded onto 12 % SDS-PAGE and subsequently trans-
ferred onto PVDF membrane (Millipore, Bedford, MA,
USA). The membrane was blocked by incubation for 2 h
at room temperature and incubated with mouse anti-rat
IDO antibody (Santa Cruz Biotechnology) at 4 °C for
overnight. After three washes with PBS containing
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0.05 % (v/v) Tween20, the membrane was further incu-
bated with goat anti-mouse horseradish peroxidase-
labeled secondary antibody and visualized with the eECL
detection system (Beijing CoWin Bioscience Co. Ltd,
Beijing, China). Membranes were stripped and reblotted
with an antibody for GAPDH as a loading control. Semi-
quantitative analysis of the protein density bands was
quantified using the ImageJ software (National Institutes
of Health, Bethesda, MD).
Induction of EAMG and Dex administration
EAMG were induced by subcutaneous injection into
both hind footpads with 200 μl inoculum containing
50 μg R97–116 peptide, 2 mg Mycobacterium tubercu-
losis (strain H37RA; Difco, Detroit, MI, USA) in incom-
plete Freund’s adjuvant (Sigma-Aldrich) on day 0 and
were boosted with the same dose along the back on day
11 after the first immunization. The severity of the dis-
ease was scored by measuring muscular weakness in a
blinded fashion from the beginning of the experiment
every second day until day 43 p.i. Clinical scoring was
based on the presence of tremor, hunched posture,
muscle strength, and fatigability. Fatigability was
assessed after exercise (repetitive paw grips on the cage
grid) for 30 s. The severity of clinical symptoms was
scored as follows [3, 15]: 0, normal strength and no ab-
normalities; 1, mildly decreased activity and weak grip or
cry, more evident at the end of exercise; 2, clinical signs
present before exercise (tremor, head down, hunched
posture, weak grip); 3, severe clinical signs present be-
fore exercise, no grip, moribund; 4, dead. Rats with
intermediate signs were assigned scores of 1.5, 2.5, or
3.5. Results are expressed as the mean of the evaluations
recorded for each animal at each time point.
In our present study, the method and dosage of Dex
administration were followed according to the studies by
Kim et al. and Duchmann et al. [35, 36]. Statin-Dex and
control-Dex were transferred into EAMG rats via tail
vein injection at dose of 10 μg/rat on days 5 and 16 p.i.
The control rats received the same volume of PBS.
Tracking analysis and the effect of statin-Dex injection on
endogenous DCs
To examine the mechanism of action of Dex in vivo, the
tracking of injected Dex was examined in EAMG rats.
Statin-Dex and control-Dex were labeled with PKH26
(red florescent cell linker; Sigma) as outlined by the
manufacturer. After incubation with the linker, the la-
beled Dex were washed twice by ultracentrifugation and
then intravenously injected into EAMG rats at dose of
10 μg/rat on day 5 p.i. Rats were killed on days 1 and 3
after injection, and the tissues (spleen, liver, thymus,
popliteal, and inguinal lymph nodes) were obtained and
frozen for histological analysis. Cryostat sections (6 μm)
were made from these samples and examined by fluores-
cence microscopy (Olympus FSX100, Tokyo, Japan).
Meanwhile, spleen-derived DCs from EAMG rats were
prepared as previous methods [15]. Briefly, spleens were
removed under aseptic conditions from EAMG rats on
days 1 and 3 after injection of PKH26-labeled Dex, re-
spectively. Mononuclear cell (MNC) suspensions from
individual rats were obtained by grinding the spleens
through cell strainers (Becton Dickenson) in medium.
Then, erythrocytes were osmotically lysed. Spleen-
derived DCs were further enriched by differential adher-
ence by incubating cells in 25 mm2 Falcon culture flasks
(Becton Dickinson) in serum-free RPMI 1640 (contain-
ing 2.05 mM glutamine, HyClone) at 37 °C in a 5 % CO2
incubator. After 1 h 40 min, non-adherent cells were
gently removed by swirling the flasks and aspirating the
medium, then flasks were washed with serum-free
medium to remove non-adherent cells. New RPMI 1640
medium containing 1 % (v/v) minimum essential
medium (MEM; Sigma-Aldrich), 50 μg/ml gentamicin
(Shandong Lukang), and 10 % FCS (Gibco) (depleted of
contaminating vesicles and protein aggregates under-
went overnight centrifugation at 110,000×g) were added
to the flasks. After 4-h incubation, floating cells were
collected as a spleen-derived DCs-enriched fraction.
Thereafter, we labeled these spleen-derived DCs (en-
dogenous DCs) with FITC-conjugated anti-rat CD80
(AbD Serotec, Oxford, UK), FITC-conjugated anti-rat
CD86 (BioLegend), and FITC-conjugated anti-rat MHC
class II (eBioscience) for 30 min at 4 °C. Then, the
percentages of PKH26-labeled endogenous DCs and the
expression of CD80, CD86, and MHC class II on en-
dogenous DCs were examined by flow cytometry (BD
Biosciences, San Jose, CA, USA). The whole operation
process was in dark.
To further investigate the mechanism of exogenous
Dex injection on endogenous DCs, spleen-derived DCs
from ongoing EAMG rats were cultured with PKH26-
labeled statin-Dex and control-Dex in vitro, respectively.
Following, these DCs were labeled with mouse anti-rat
OX62 antibody and FITC-conjugated anti-mouse IgG
antibody (green). Then, the labeled DCs were examined
by fluorescence microscopy (Olympus FSX100).
Immunohistochemistry
Segments of thymuses were dissected from EAMG
rats. Paraffin tissue sections (5 μm) were deparaffi-
nized and hydrated. The sections were treated with
0.3 % hydrogen peroxide for 20 min to block
endogenous peroxidase activity. After three washes in
PBS, the sections were boiled in citrate buffer for
antigen retrieval and incubated overnight at 4 °C with
mouse anti-rat Foxp3 antibody (1:100; eBioscience).
Then, the sections were stained with horseradish
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peroxidase-conjugated goat anti-mouse secondary
antibody (Zhongshan Goldenbridge Biotechnology,
Beijing, China), followed by development with
diaminobenzidine (DAB) substrate (Zhongshan Gold-
enbridge Biotechnology) to detect the number of
Foxp3+ cells. As negative controls for immunostain-
ing, the primary antibody was omitted. The tissue
areas were measured by image analysis in five sec-
tions per thymus, and the results were expressed as
the number of positive cells per square millimeter
tissue section.
Preparation of lymph node MNC
On day 43 p.i., EAMG rats were sacrificed and inguinal
lymph nodes were removed under aseptic conditions.
MNC suspensions were obtained by grinding the organs
through cell strainers in serum-free medium. Then, cells
were washed three times and re-suspended to 2 × 106/ml
in RPMI 1640 (HyClone) supplemented with 1 % (v/v)
MEM (Sigma-Aldrich), 50 μg/ml gentamicin (Shandong
Lukang Cisen), and 10 % (v/v) FCS (Gibco) for the fol-
lowing experiments.
Flow cytometric analysis of lymph node MNC
Fixation and permeabilization of lymph node MNC were
performed using the eBioscience Foxp3 Staining Buffer
Set (eBioscience). FITC-conjugated anti-rat CD4, PE-
conjugated anti-rat CD25, and PE-Cy5-conjugated anti-
mouse/rat Foxp3 antibodies (all from eBioscience) were
used for staining Treg cells according to the protocol
recommended by eBioscience. For intracellular cytokines
analysis, MNC were fixed with 2 % paraformadehyde for
20 min at 4 °C and permeabilized with 0.5 % saponin.
Then, the cells were stained with PE-conjugated anti-rat
IL-10 (Pharmingen, San Diego, CA, USA) and FITC-
conjugated anti-rat TNF-α antibodies (BioLegend) for
30 min at 4 °C. For cell surface molecules, MNC suspen-
sions in PBS containing 0.5 % BSA (Sigma-Aldrich) were
incubated with FITC-conjugated anti-rat Fas antibody
(Santa Cruz Biotechnology) for 30 min at 4 °C in the
dark. For apoptosis analysis, MNC suspensions were
washed twice with cold BioLegend cell staining buffer
and then re-suspend cells in Annexin V Binding Buffer.
Then, 100 μl of cell suspensions were transferred to an-
other test tube. Five microliters of FITC-Annexin V and
10 μl of propidium iodide (PI) solution incubate were
added for 15 min at room temperature in the dark.
Then, the cells were analyzed by flow cytometry (BD
Biosciences).
Analysis of cell viability
Cell viability was assessed by Cell Counting Kit-8 (CCK-
8). Briefly, MNC suspended in 200 μl aliquots containing
4 × 105 cells were cultured in triplicates in flat-bottomed
96-well microtitre plates (Corning, NY, USA) in the
presence of PBS, R97–116 peptide (10 μg/ml), or ConA
(5 μg/ml). After 72 h of incubation, the cells were incu-
bated with 10 μl CCK-8 for 4 h at 37 °C. Then, the ab-
sorbance was read at 450 nm on a microplate reader.
Data are expressed as mean absorbance value (optical
density (OD)) of samples ± standard deviation (SD).
Determination of cytokines in culture supernatants by
ELISA
Quantitative analysis of IFN-γ and IL-4 levels was per-
formed by ELISA. MNC were cultured in the presence
of R97–116 peptide (10 μg/ml). After 72 h incubation at
37 °C, the supernatants were collected and measured for
IFN-γ and IL-4 by sandwich ELISA kits (both from
eBioscience) following the manufacturer’s instructions.
Determinations were performed in duplicate and the re-
sults were expressed as picogram per milliliter.
ELISA for serum anti-R97–116 peptide IgG antibody and
its subtype
A standard ELISA technique was used to detect R97–
116 peptide specific antibody. Briefly, R97–116 peptide
(5 μg/ml) was coated onto a flat-bottomed 96-well mi-
crotitre plates (Corning) in 0.1 M carbonate bicarbonate
buffer (pH 9.6) overnight at 4 °C. Then, the plates were
blocked with 200 μl of PBS containing 0.05 % Tween20
and 10 % FCS at 37 °C for 1.5 h. A total volume of
100 μl diluted serum samples (1:100 in PBS/0.05 %
Tween20) were added and incubated for 2 h at room
temperature. After washed, biotin rabbit anti-rat IgG
(1:3000; Biosynthesis Biotechnology, Beijing, China), bio-
tin anti-rat IgG1, IgG2a, and IgG2b (1:500; BioLegend)
were added to the wells and incubated for 1 h. Then
streptavidin-horseradish peroxidase (1:1000; Biosynthesis
Biotechnology) was added, incubated at 37 °C for
30 min. Then, plates were washed with PBS containing
0.05 % Tween20 and followed by development with
Tetramethylbenzidine (TMB) substrate (Tiangen Bio-
technology, Beijing, China). Finally, plates were read at a
wave length of 450 nm using a microplate ELISA reader.
Each serum was tested in triplicate. Results are
expressed as mean OD value of samples ± SD.
FasL neutralization assays
To examine the effect of FasL on EAMG rats, statin-
Dex were incubated with purified Hamster anti-
Mouse and rat FasL blocking (0.1, 1, and 10 μg /ml)
or purified Hamster IgG3, κ isotype control anti-
bodies (10 μg/ml) (both from BD Pharmingen) as a
negative control at 37 °C for 12 h followed by wash-
ing three times. Then, the neutralized statin-Dex were
analyzed by flow cytometry, and the optimal neutral-
izing concentration was used for in vivo studies.
Li et al. Journal of Neuroinflammation  (2016) 13:8 Page 5 of 18
Following, statin-Dex blocked with anti-FasL or iso-
type antibodies were transferred into EAMG rats via tail
vein injection at dose of 10 μg/rat on days 5 and 16 p.i.,
respectively. EAMG rats were scored from the beginning
of the experiment every second day until day 43 p.i. The
severity of clinical symptoms was scored as previous
mentioned.
On day 43 p.i., EAMG rats were sacrificed and in-
guinal lymph nodes were removed under aseptic condi-
tions. MNC suspensions were obtained and re-
suspended to 2 × 106/ml in RPMI 1640 (HyClone). For
cell surface molecules, MNC suspensions were incu-
bated with FITC-conjugated anti-rat Fas antibody (Santa
Cruz Biotechnology) for 30 min at 4 °C. After staining,
the cells were re-suspended in PBS and analyzed by flow
cytometry (BD Biosciences). For apoptosis analysis,
MNC suspensions were stained with FITC-Annexin V
and PI solution. Then, the cells were analyzed by flow
cytometry (BD Biosciences).
Meanwhile, serums in different time points (days 10,
21, 32, and 43 p.i.) were collected for detection of anti-
R97–116 peptide IgG antibody and its subtype (IgG1,
IgG2a, and IgG2b).
Statistical analysis
The SPSS 17.0 computer program (SPSS Inc., Chicago,
IL, USA) was used for all calculations and statistical
evaluations. Differences were tested by two-tailed Stu-
dent t test between two groups and by one-factor ana-
lysis of variance (ANOVA) followed by post hoc test
among three groups. p < 0.05 was considered significant.
Results
Characterization of rat Dex
To examine the composition of Dex, DCs were gener-
ated from the bone marrow precursors of ongoing
EAMG rats and cultured in the presence of rrGM-CSF
and rrIL-4. Then, Dex were isolated from the culture
medium by differential centrifugation and characterized
by electron microscopy, flow cytometry, and western
blotting. Ultrastructural analysis of Dex by transmission
electron microscopy showed a significant enrichment of
the characteristic saucer-shaped vesicles, 30–100 nm in
diameter (Fig. 1a). We further examined the surface pro-
teins on the Dex by flow cytometry. Flow cytometric
analysis showed that statin-Dex had lower level of MHC
class II and higher level of FasL when compared with
control-Dex (p < 0.001 for both comparisons) (Fig. 1b).
Meanwhile, statin-Dex carried higher level of IDO pro-
tein when compared with control-Dex, confirmed by
Western blotting analysis (Fig. 1c). Taken together, these
data demonstrated that atorvastatin induced the produc-
tion of tolerogenic Dex, and these tolerogenic Dex (sta-
tin-Dex) might play their immunoregulatory roles by
lower level of MHC class II and high levels of FasL as
well as IDO protein.
Statin-Dex treatment suppress the development of EAMG
To investigate the immunoregulatory effects of statin-
Dex, EAMG rats were injected intravenously with
statin-Dex, control-Dex, or the same volume of PBS
on days 5 and 16 p.i. The rats in statin-Dex group
exhibited lower clinical scores when compared with
the rats in control-Dex group (p < 0.05 and p < 0.01)
and control group (p < 0.05). Moreover, the clinical
symptoms between control-Dex group and control
group did not differ significantly (Fig. 2). None of rats
of the three groups died during the observation until
day 43 p.i. These results showed that Dex with lower
level of MHC class II and higher levels of FasL and
IDO protein could contribute to the protective effects
on EAMG.
Dex tracking in vivo and in vitro
To determine the fate of Dex following injection, we
labeled statin-Dex and control-Dex with PKH26 red
fluorescent cell linker and intravenously injected them
into EAMG rats on day 5 p.i. Then, we dissected the
spleen, liver, thymus, popliteal, and inguinal lymph
nodes on days 1 and 3 after injection. As shown in
Fig. 3a, both labeled statin-Dex and control-Dex were
detected in the spleen, thymus, and popliteal and in-
guinal lymph nodes, but were absent in liver. More-
over, less labeled Dex was found on day 3 after
injection when compared with those on day 1 after
injection. These labeled statin-Dex and control-Dex
were mainly located in the red pulp of spleen and the
cortex of thymus, while the labeled Dex could be
found to be distributed diffusely within the lymph
nodes. These characteristics of distribution indicated
that statin-Dex could play their immunomodulatory
effects in the immune organs of EAMG rats. In order
to clarify the effects of exogenous Dex on endogenous
DCs after injection in EAMG rats, we detected the
expression of CD80, CD86, and MHC class II on en-
dogenous DCs on days 1 and 3 after injection of
PKH26-labeled exogenous Dex. Interestingly, the re-
sults showed that endogenous DCs from EAMG rats
of statin-Dex group expressed lower level of CD80 on
day 1 after injection and lower levels of CD80, CD86,
and MHC class II on day 3 after injection when com-
pared with those from control-Dex group (for CD80,
p < 0.05 on days 1 and 3 after injection; for CD86 and
MHC class II, p < 0.001 on day 3 after injection).
There were no significant differences for the levels of
CD86 and MHC class II expressed on endogenous
DCs from EAMG rats on day 1 after injection
between statin-Dex group and control-Dex group
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(Fig. 3b). Moreover, the percentages of PKH26-labeled
endogenous DCs (both statin-Dex group and control-
Dex group) on days 1 and 3 after injection were very
low (both means <2.5 %), which indicated that only
few exogenous Dex can be fused with and expressed
on the surface of endogenous DCs (Fig. 3c). As
shown in Fig. 3d, both statin-Dex and control-Dex
could be internalized by or fused with spleen-derived
DCs in vitro (red stands for Dex, green stands for
DCs, and yellow refers to overlap of red and green).
Statin-Dex treatment increase the number of Foxp3+ cells
in thymus of EAMG rats
Thymuses were taken from statin-Dex group, control-
Dex group and control group rats on day 43 p.i. for
immunohistochemistry analysis. We found that statin-
Dex treatment increased the number of Foxp3+ cells
in thymus when compared with control-Dex and PBS
treatments (Fig. 4a). Further analysis showed that the
number of Foxp3+ cells in statin-Dex group was
higher than those in control-Dex group and control
group (p < 0.001 for both comparisons), while there
was no difference between control-Dex group and
control group (Fig. 4b). These data indicated that the
mild EAMG clinical scores in statin-Dex group were
associated with the increased number of Foxp3+ cells
in thymus.
Fig. 1 Characterization of rat Dex. To examine the composition of Dex, DCs were generated from the bone marrow precursors of ongoing EAMG
rats (n = 40). Then, Dex were isolated from the culture medium of statin-BMDCs and control-BMDCs by differential centrifugation and character-
ized by electron microscopy (a), flow cytometry (b), and western blotting (c) (***p < 0.001)
Fig. 2 Statin-Dex treatment suppresses the development of ongoing
EAMG in Lewis rats. Statin-Dex and control-Dex were transferred into
EAMG rats via tail vein injection at dose of 10 μg/rat on days 5 and
16 p.i. The control rats received the same volume of PBS (n = 5 rats
per group). The rats in statin-Dex group exhibited lower clinical
scores when compared with rats in control-Dex group (*p < 0.05 and
**p < 0.01) and control group (#p < 0.05), while the clinical symptoms
between control-Dex group and control group did not differ signifi-
cantly. The data are expressed as mean ± SD and representative of
two independent experiments
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Fig. 3 (See legend on next page.)
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(See figure on previous page.)
Fig. 3 Distribution of Dex after injection into the EAMG rats and effects of statin-Dex injection on endogenous DCs. The PKH26-labeled (red) Dex
were detected in the spleen, thymus, and popliteal and inguinal lymph nodes on days 1 and 3 after injection (a, original magnification ×100).
The expression of CD80, CD86, and MHC class II on endogenous DCs on days 1 and 3 after injection were examined by FACS. The results showed
that endogenous DCs from EAMG rats of statin-Dex group expressed lower level of CD80 on day 1 after injection and lower levels of CD80,
CD86, and MHC class II on day 3 after injection when compared with those from control-Dex group. There were no significant differences for the
levels of CD86 and MHC class II expressed on endogenous DCs from EAMG rats on day 1 after injection between statin-Dex group and control-
Dex group (b). To further investigate the mechanism of exogenous Dex injection on endogenous DCs, spleen-derived DCs from ongoing EAMG
rats were cultured with PKH26-labeled (red) statin-Dex and control-Dex in vitro, respectively. The percentages of PKH26-labeled endogenous DCs
were examined by flow cytometry (c). Meanwhile, these DCs were labeled with mouse anti-rat OX62 antibody and FITC-conjugated anti-mouse
IgG antibody (green). Then, the labeled DCs were examined by fluorescence microscopy. Both statin-Dex and control-Dex could be internalized
by or fused with spleen-derived DCs in vitro (red stands for Dex, green stands for DCs, and yellow refers to overlap of red and green) (The
diameter of spleen-derived DCs from rats is about 10–20 μm) (d, original magnification ×400). The results are expressed as mean ± SD (n = 5 rats
per group) (*p < 0.05 and ***p < 0.001)
Fig. 4 Statin-Dex treatment increases the number of Foxp3+ cells in thymus of EAMG rats. The number of Foxp3+ cells in thymus of EAMG
rats was analyzed by immunohistochemistry. Statin-Dex, control-Dex, and PBS were transferred into EAMG rats via tail vein injection. Rats were
sacrificed on day 43 p.i. a Representative micrographs show more Foxp3+ cells in the thymus in rats treated with statin-Dex compared to those
in control-Dex and control rats, respectively. The arrow referred to typical Foxp3+ cells and the nucleus was filled with brown. Original magnification,
×200 and ×400. b The number of Foxp3+ cells per mm2 thymus sections is expressed as mean ± SD (n= 5 rats per group) (***p < 0.001)
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Statin-Dex treatment increase the number of CD4+Foxp3+
T cells in lymphocytes
To examine whether the effects of statin-Dex treatment
were correlated with Treg cells in EAMG rats, MNC
from lymph nodes on day 43 p.i. were stained with
FITC-conjugated anti-rat CD4, PE-conjugated anti-rat
CD25, and PE-Cy5-conjugated anti-mouse/rat Foxp3
antibodies. The results showed that statin-Dex treatment
increased the percentage of CD4+Foxp3+ T cells among
lymph node MNC when compared to control-Dex and
PBS treatments (p < 0.05 for both comparisons), while
there was no difference for the percentage of CD4+CD25
+ T cells. Meanwhile, there was no difference for the per-
centages of CD4+CD25+ T cells and CD4+Foxp3+ T cells
between control-Dex group and control group (Fig. 5a,
b).
Effects of statin-Dex treatment on the expression of intra-
cellular cytokines in lymphocytes and on the lymphocyte
proliferation
To gain insight into the mechanism underlying the effect
of statin-Dex on EAMG, intracellular cytokines among
Fig. 5 Statin-Dex treatment increase the number of CD4+Foxp3+ T cells in lymphocytes. Expressions of CD4+CD25+ T cells and CD4+Foxp3+ T
cells among lymph node MNC in statin-Dex group, control-Dex group, and control group were detected by FACS. The results showed that statin-
Dex treatment increased the percentage of CD4+Foxp3+ T cells among lymph node MNC when compared with control-Dex and PBS treatments,
while there was no difference for the percentage of CD4+CD25+ T cells. Meanwhile, we did not observe difference in the percentages of CD4
+CD25+ T cells and CD4+Foxp3+ T cells between control-Dex group and control group (a, b). The results are expressed as mean ± SD (n = 5 rats
per group) (*p < 0.05)
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lymph node MNC on day 43 p.i. were determined by
flow cytometry. We found that there was no significant
difference for the expression of IL-10+ and TNF-α+ cells
among the three groups (data not shown). In order to
investigate the antigen-specific lymphocyte response
among statin-Dex group, control-Dex group, and control
group, lymphocyte proliferation was measured after 72 h
of culture in the presence of PBS, R97–116 peptide or
ConA by using the CCK-8 assay. We observed that there
was no difference among the three groups when MNC
cultured with PBS and R97–116 antigen, although there
was significant cell proliferation for ConA stimulation
(data not shown). The data indicated that statin-Dex
treatment on EAMG rats did not inhibit the prolifera-
tion of R97–116 antigen-specific T lymphocytes.
Effects of statin-Dex treatment on the expression of Fas
on lymph node MNC and analysis of apoptosis
In our study, we found that statin-Dex carried higher
level of FasL; to examine whether statin-Dex could
induce cell apoptosis through FasL/Fas pathway, the
expression of Fas on lymph node MNC and the dis-
tribution of apoptotic lymphocytes were measured by
flow cytometry. The results showed that statin-Dex
treatment increased the percentage of Fas+ cells on
lymph node MNC when compared with control-Dex
and PBS treatments (p < 0.05 and p < 0.01, respect-
ively), while there was no difference between control-
Dex group and control group (Fig. 6a). For apoptosis
analysis, on the image from the flow cytometry, cells
in the upper-left portion (Q1), the upper-right portion
(Q2), the lower-left portion (Q3), and the lower-right
portion (Q4) represent dead cells, late-apoptotic cells
+ necrotic cells, viable cells, and early-apoptotic cells,
respectively. In our present study, we observed that
the numbers of apoptotic cells were not different
among the three groups of rats, which indicated that
FasL/Fas pathway might not be the main mechanism
involved in the induction of cell apoptosis (Fig. 6b).
Effects of statin-Dex treatment on the levels of IFN-γ and
IL-4 in the culture supernatants
To further investigate the mechanisms of statin-Dex
treatment on EAMG, we examined the levels of IFN-
γ and IL-4 in culture supernatants of lymphocytes
stimulated with R97–116 peptide. The results showed
that statin-Dex treatment did not change the level of
IFN-γ when compared with control-Dex and PBS
treatments (data not shown). Moreover, there was al-
most no detectable IL-4 in culture supernatants of
the three groups (data not shown). These data indi-
cated that statin-Dex treatment did not disturb the
balance of Th1 and Th2 responses in EAMG rats.
Effects of statin-Dex treatment on the levels of anti-R97–
116 peptide IgG antibody and its subtype in serum
In our present study, blood samples were collected
on days 10, 21, 32, and 43 p.i. to determine the
Fig. 6 Effects of statin-Dex treatment on the expression of Fas on lymph node MNC and analysis of apoptosis. To examine whether statin-Dex
could induce cell apoptosis through FasL/Fas pathway, the expression of Fas on lymph node MNC (a) and the distribution of apoptotic lympho-
cytes (b) were measured by flow cytometry. The results are expressed as mean ± SD (n = 5 rats per group) (*p < 0.05 and **p < 0.01)
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production of anti-R97–116 peptide IgG antibody and
its subtypes IgG1, IgG2a, and IgG2b by ELISA. Rats
treated with statin-Dex had lower levels of serum
anti-R97–116 IgG, IgG2a, and IgG2b antibodies com-
pared with control-Dex group rats (for IgG: p < 0.05
on day 21 p.i., p < 0.001 on day 43 p.i.; for IgG2a: p <
0.001 on day 32 p.i., p < 0.05 on day 43 p.i.; for IgG2b: p
< 0.001 on day 21 p.i., p < 0.01 on day 43 p.i.) and control
group rats (for IgG: p < 0.05 on day 43 p.i.; for IgG2a: p <
0.05 on days 32 and 43 p.i.; for IgG2b: p < 0.05 on days 21
and 43 p.i.). No significant difference in serum anti-R97–
116 IgG antibody and its subtype was found between
control-Dex group rats and control EAMG rats at differ-
ent time points. Meanwhile, there was no statistical differ-
ence for anti-R97–116 IgG1 antibody among the three
groups at different time points (Fig. 7).
Benefits from statin-Dex treatment on EAMG rats are
partly FasL/Fas pathway dependent
To further investigate the involvement of FasL in
statin-Dex-induced apoptosis, we treated statin-Dex
with anti-FasL blocking or isotype control antibody.
In the presence of anti-FasL blocking antibody (final
concentration: 10 μg/ml), the level of FasL on statin-
Dex was decreased (Fig. 8a). Thereafter, statin-Dex
blocked with anti-FasL or isotype antibody were
transferred into EAMG rats via tail vein injection,
respectively. The rats in statin-Dex with anti-FasL
blocking antibody group exhibited higher clinical
scores when compared with the rats in statin-Dex
with isotype control antibody group (Fig. 8b). The
results showed that there were significant decreases
in both the level of Fas+ cells on lymph node MNC
and the number of early-apoptotic cells in statin-Dex
with anti-FasL blocking antibody group. Meanwhile,
there was no significant difference for the number of
late-apoptotic cells + necrotic cells between statin-Dex
with anti-FasL blocking antibody group and statin-
Dex with isotype control antibody group (Fig. 9a, b).
Fig. 7 Effects of statin-Dex treatment on the levels of anti-R97–116
peptide IgG antibody and its subtype in serum. Rats treated with
statin-Dex had lower levels of serum anti-R97–116 IgG, IgG2a, and
IgG2b antibodies compared with control-Dex group rats (for IgG
*p < 0.05 on day 21 p.i., ***p < 0.001 on day 43 p.i.; for IgG2a ***p <
0.001 on day 32 p.i., *p < 0.05 on day 43 p.i.; for IgG2b ***p < 0.001
on day 21 p.i., **p < 0.01 on day 43 p.i.) and control group rats (for
IgG #p < 0.05 on day 43 p.i.; for IgG2a #p < 0.05 on days 32 and 43
p.i.; for IgG2b #p < 0.05 on days 21 and 43 p.i.). No significant differ-
ence in serum anti-R97–116 IgG antibody and its subtype was found
between control-Dex group rats and control EAMG rats at different
time points. Meanwhile, there was no statistical difference for anti-
R97–116 IgG1 antibody among the three groups at different time
points. Each serum was tested in triplicate. All results are expressed
as mean ± SD (n = 5 rats per group)
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These data suggested that anti-FasL blocking anti-
body, but not isotype control antibody, almost
completely blocked statin-Dex treatment-induced cell
apoptosis in EAMG rats. Meanwhile, statin-Dex with
anti-FasL blocking antibody treatment resulted in
higher levels of serum anti-R97–116 IgG, IgG2b anti-
bodies on day 10 p.i. (p < 0.01 for both comparisons)
and lower level of IgG1 antibody on day 43 p.i. (p <
0.01) when compared with statin-Dex with isotype
control antibody treatment (Fig. 10). Taken together,
our data indicated that statin-Dex treatment could in-
duce cell apoptosis partly through FasL/Fas dependent
mechanism, which would further lead to reduction of
pathogenic anti-R97–116 IgG, IgG2a, and IgG2b
antibodies.
Discussion
In the present study, DCs were generated from bone
marrow precursors of EAMG rats on day 22 p.i. Dex
were prepared from the cell culture supernatants of
statin-BMDCs and control-BMDCs, respectively. Com-
pared with control-Dex, statin-Dex carried lower level of
MHC class II and higher levels of FasL and IDO. We ad-
ministrated statin-Dex, control-Dex, or PBS into EAMG
rats via tail vein injection on days 5 and 16 p.i. Although
the clinical symptoms were not significant on days 5 and
16 p.i., the immune response in vivo was activated in the
early stage of disease. Therefore, we assumed that statin-
Dex administrated in EAMG rats on days 5 and 16 p.i.
played their therapeutic efficacy in ameliorating the dis-
ease. Our results confirmed that statin-Dex treatment
suppressed clinical symptoms of EAMG compared with
control-Dex and PBS treatments. After injection, these
statin-Dex were detected in the spleen, thymus, and
popliteal and inguinal lymph nodes. Furthermore, statin-
Dex exerted their immunomodulatory effects in EAMG
rats by decreasing the expression of CD80, CD86, and
MHC class II on endogenous DCs. Finally, the thera-
peutic effects of statin-Dex on EAMG rats were associ-
ated with up-regulated level of IDO on statin-Dex and
increased Treg cells in the thymus and lymph nodes. In
addition, the effects of statin-Dex on EAMG were partly
dependent on FasL/Fas pathway.
It is reported that Dex can transfer regulatory mole-
cules to their corresponding acceptor cells. Exosomes
containing MHC class II molecule as well as other pro-
teins can attach to the surface of follicular DCs (FDCs).
Thus, these FDCs passively acquire MHC class II mol-
ecule or other proteins from these donor exosomes [37].
Exosomes can be internalized by or fused with DCs and
then processed by DCs for antigen presentation to CD4+
T cells [38]. Montecalvo et al. observed that exosomes
first bound to the APCs surface and then internalized
into endocytic vesicles of immature and mature DCs
[39]. In our study, exogenous statin-Dex induced lower
expression levels of CD80, CD86, and MHC class II on
endogenous DCs when compared with control-Dex.
Meanwhile, exogenous statin-Dex or control-Dex can be
fused with endogenous DCs. We also found that both
statin-Dex and control-Dex were captured and internal-
ized by spleen-derived DCs in vitro. This indicates that
the labeled Dex could be internalized by endogenous
DCs and then processed for presentation of antigens to
CD4+ T cells. Taken together, our data confirmed that
exogenous statin-Dex played their roles by decreasing
the expression of CD80, CD86, and MHC class II on en-
dogenous DCs, which could further induce T cell anergy
and immune tolerance in EAMG rats. These endogen-
ous immature DCs may also increase the number of
Treg cells in EAMG rats.
Fig. 8 a The neutralized statin-Dex were analyzed by flow cytometry.
Statin-Dex were incubated with purified Hamster anti-Mouse and rat
FasL blocking (0.1, 1, and 10 μg/ml) or purified Hamster IgG3, κ isotype
control antibodies (10 μg/ml). In the presence of anti-FasL blocking
antibody (final concentration 10 μg/ml), the level of FasL expressed on
statin-Dex were significantly decreased. The results are expressed as
mean ± SD (*p < 0.05). b Effects of statin-Dex blocked with anti-FasL
antibody on the development of EAMG in Lewis rats. Statin-Dex
blocked with anti-FasL or isotype antibodies were transferred into
EAMG rats via tail vein injection at dose of 10 μg/rat on days 5 and 16
p.i., respectively. The rats in statin-Dex with anti-FasL blocking antibody
group exhibited higher clinical scores when compared with rats in
statin-Dex with isotype control antibody group (*p < 0.05 and **p <
0.01). The data are expressed as mean ± SD (n = 6 rats per group)
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MHC class II molecule, which is expressed on APCs
(such as DCs and B cells), is required for presenting
antigen peptides to T cells. DCs- or B cell-derived exo-
somes carrying MHC class II peptide complexes could
transfer allogeneic antigen to T cells or other APCs dur-
ing the induction of immune responses and tumor rejec-
tion [40, 41]. Exosomes from class II trans-activator
(CIITA)-transduced murine melanoma cells contain a
large amount of MHC class II and exhibit greater effects
on tumor regression [42]. Circulating MHC class II+
exosomes in tumor-bearing hosts are able to suppress
the immune responses specific to tumor antigens [43].
As compared with mDex, iDex shows less enriched in
MHC class II and CD86 as well as ICAM-1 and less po-
tent for antigen-specific T cell activation [44]. In our
study, statin-Dex showed lower levels of MHC class II
when compared with control-Dex. However, our data
did not provide evidence for the inhibitory effects of
statin-Dex treatment on proliferation of R97–116
antigen-specific T lymphocytes. This suggests that MHC
class II molecule derived from statin-Dex might not
mainly be responsible for presentation of antigens to T
cells in EAMG. Meanwhile, statin-Dex treatment did
not change the percentage of IL-10+ and TNF-α+ cells
and the level of IFN-γ compared with control-Dex and
PBS treatments. There was almost no detectable IL-4 in
culture supernatants in all the three groups. This
indicates that statin-Dex treatment may not disturb the
balance between Th1 and Th2 responses in EAMG rats.
Consistently, Mallegol et al. have shown that DCs-
derived MHC class II molecule, but not exosome-
derived MHC class II molecule, is responsible for
presentation of antigens to T cells [45]. Therefore, the
mechanisms underlying the effects of statin-Dex on
EAMG still need further investigation.
Recently, the immunosuppressive roles of IDO have
been widely investigated in rheumatoid arthritis (RA)
[46], tumor [47], transplantation [48], and EAE [49].
Several studies have demonstrated the association be-
tween the expression of IDO in DCs and the induction
of Treg cells in different physiological and pathological
settings. It is reported that the induction of IDO activity
in DCs (IDO-competent DCs) promoted the differenti-
ation of naïve CD4+ T cells into Foxp3+ Treg cells and
Fig. 9 Effects of statin-Dex blocked with anti-FasL antibody on the expression of Fas on lymph node MNC and analysis of apoptosis. On day 43
p.i., EAMG rats were sacrificed and inguinal lymph nodes were removed under aseptic conditions. MNC suspensions were obtained. The percent-
age of Fas+ cells on lymph node MNC and the distribution of apoptotic lymphocytes were measured by flow cytometry (a, b). The results are
expressed as mean ± SD (n = 6 rats per group) (*p < 0.05)
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induced the activation and regulatory function of quies-
cent Treg cells [50, 51]. Gut CD103+ DCs with IDO ex-
pression in the gut is reported to induce Foxp3+ Treg
cells differentiation and inhibit IL-17 production, thus
contributing to intestinal homeostasis [52]. Enhanced
expression of IDO in splenic IDO+ CD11b+ DCs is asso-
ciated with impaired proliferation of type II collagen
(CII)-reactive T cells, and with CII-activated increase in
converted Treg cells and Treg/Th17 ratio [53]. However,
it is still unknown whether exosomes over-carrying IDO
could activate Treg cells. In our present study, statin-
Dex exhibited higher level of IDO when compared with
control-Dex, suggesting that statin-Dex over-carrying
IDO may increase the number and/or function of Treg
cells and further be involved in immunomodulation.
Consistent with our speculation, EAMG rats adminis-
trated with statin-Dex showed significantly increased
numbers of Foxp3+ cells in the thymus and CD4+Foxp3+
T cells in MNC from the lymph nodes when compared
with control-Dex group and control group. Therefore,
we conclude that these Treg cells play important roles in
maintaining immunologic tolerance of EAMG.
Ligation of FasL to Fas triggers the activation of cas-
pases (such as caspase-8, caspase-3, caspase-6, and
caspase-7) and eventually leads to apoptosis, even to cell
death [54]. It has been demonstrated that FasL expressed
on exosomes released by tumor cells could induce CD8+
T cell apoptosis [55]. The suppressive ability of the DC/
FasL-derived exosomes on the DTH response is
dependent not only on FasL in the DCs-derived exo-
somes but also on the presence of Fas in the host mice
[36]. At the beginning of the neoplastic process, tumor
cell-derived exosomes selectively induce apoptosis of
antigen-specific T cells, which in turn up-regulate ex-
pression of Fas on the T cells. Thus, the FasL expressed
on exosomes could induce apoptosis of T cells by bind-
ing with Fas [56]. These results indicate that the inter-
action between FasL and Fas is dependent on each
other’s existence. In our study, statin-Dex carried higher
level of FasL compared with control-Dex and statin-Dex
treatment increased the number of Fas+ cells on lymph
node MNC. However, our data showed that there was
no significant difference among the three groups in the
numbers of apoptotic cells. Consistent with our results,
Fig. 10 Effects of statin-Dex blocked with anti-FasL antibody on the
levels of anti-R97–116 peptide IgG antibody and its subtype. Serums
in different time points (days 10, 21, 32, and 43 p.i.) were collected
for detection. Statin-Dex with anti-FasL blocking antibody treatment
resulted in higher levels of serum anti-R97–116 IgG and IgG2b anti-
bodies on day 10 p.i., and lower level of IgG1 antibody on day 43
p.i. when compared with statin-Dex with isotype control antibody
treatment. Each serum sample was tested in triplicate. All results are
expressed as mean ± SD (n = 6 rats per group) (**p < 0.01)
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Kim et al. found that exosomes from DC/FasL did not
increase the level of apoptosis in the lymph nodes and
spleen, and the suppression of the DTH response re-
quired Fas in the recipient mice [23]. Reportedly, death
of peripheral T cells is mainly mediated by two factors:
the death receptor Fas (which is part of the extrinsic
pathway) and the pro-apoptotic molecule BIM (BCL-2-
interacting mediator of cell death) (which is part of the
intrinsic pathway). Recent studies have proposed that
BIM plays a major role in the induction of T cell apop-
tosis. It has been shown that BIM is crucial for the ter-
mination of the immune response against acute
infection with herpes simplex virus (HSV) [57]. In con-
trast, loss of Fas does not affect the immune response to
acute HSV infection [57]. Our results showed that al-
though Fas/FasL was increased, statin-Dex treatment did
not increase apoptosis of T cells in EAMG rats. This in-
dicates that Fas/FasL extrinsic pathway might not play a
major role in the apoptosis of T cells. It has been re-
ported that administration of exosomes derived from
DC/IL-4 was able to modulate the activity of APCs and
T cells in vivo through a MHC class II and partly FasL/
Fas-dependent mechanism, resulting in effective treat-
ment of CIA and suppression of the DTH response [36].
In our study, statin-Dex with anti-FasL blocking anti-
body group had decreased level of Fas+ cells in lymph
node MNC and decreased number of early-apoptotic
cells. Meanwhile, statin-Dex with anti-FasL blocking
antibody treatment induced higher levels of serum anti-
R97–116 IgG and IgG2b antibodies and lower level of
IgG1 antibody. And, the rats in statin-Dex with anti-
FasL blocking antibody treatment group exhibited more
severe clinical symptoms when compared with the rats
in statin-Dex with isotype control antibody treatment
group. Collectively, these results suggest that the im-
mune tolerance induced by statin-Dex treatment on
EAMG is partly dependent on the FasL/Fas pathway.
In both MG and EAMG, antibodies to AChR are dir-
ectly responsible for the destruction of the muscle end-
plate. Meanwhile, CD4+ T cells also can help B cells to
produce anti-AChR antibodies. Results in the present
study confirmed that statin-Dex treatment decreased the
levels of serum anti-R97–116 IgG, IgG2a, and IgG2b
antibodies compared with control-Dex and PBS treat-
ments. The changes in the levels of serum antibodies
were consisted with the clinical symptoms of EAMG.
The tolerogenic Dex may induce hyporesponsiveness of
T cells through DCs. However, the exact mechanism
underlying this effect of Dex is still unclear. In our
present study, statin-Dex migrated to the immune or-
gans after injection into the EAMG rats and was cap-
tured by endogenous DCs. These statin-Dex may play
roles in the induction of immune tolerance in EAMG
rats by decreasing expression of CD80, CD86, and MHC
class II on endogenous DCs. The endogenous immature
DCs, which lacks co-stimulatory molecules of CD80,
CD86, and MHC class II, could induce T cells entering
into a state of anergy or apoptosis and further result in
decrease of the synthesis of anti-R97–116 IgG and its
subtype antibodies. In addition, the decreased anti-R97–
116 IgG and its subtype antibodies also can be due to
up-regulated Treg cells.
Accumulating reports have shown that statins can
cause muscle pain and weakness, which may induce or
exacerbate MG [58, 59]. The underlying mechanisms are
associated with decreased mitochondrial activity medi-
ated by impaired coenzyme Q10 [60], as well as elevated
AChR antibody levels after statin treatment [61]. Our
study used statin-Dex rather than statin itself to treat
EAMG rats, which circumvented the statin-induced
muscular adverse effects in MG.
Conclusions
Our study demonstrated that statin-Dex had immune
regulation functions in immune organs. Meanwhile, these
tolerogenic Dex played roles on the induction of immune
tolerance in EAMG rats by inhibiting the expression of
CD80, CD86, and MHC class II on endogenous DCs. Im-
portantly, their inhibitory effects were associated with up-
regulated level of IDO/Treg and were partly dependent on
FasL/Fas pathway, which finally resulted in decreased syn-
thesis of anti-R97–116 IgG, IgG2a, and IgG2b antibodies.
However, the immune suppression of statin-Dex on
EAMG was not antigen-specific. In conclusion, our data
showed that statin-Dex modulated immune responses of
EAMG and that statin-Dex might be useful for the treat-
ment of human autoimmune diseases.
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